Ascendis Pharma Launches 2nd TransCon Product: YORVIPATH Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism
COPENHAGEN, Denmark - Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company specializing in the development of innovative therapies, has recently announced the commercial launch of its second TransCon product, YORVIPATH (palopegteriparatide). Specifically developed as a parathyroid hormone (PTH) replacement therapy, YORVIPATH is indicated for the treatment of adults suffering from chronic hypoparathyroidism. This groundbreaking therapy is now readily available to patients in Germany and Austria.
Chronic hypoparathyroidism is a rare endocrine disorder characterized by insufficient or absent secretion of parathyroid hormone (PTH) from the parathyroid glands. This hormone plays a vital role in regulating calcium and phosphate levels in the body. The absence of PTH leads to imbalances in these essential minerals, resulting in various debilitating symptoms for patients, including muscle cramps, fatigue, bone pain, and weakened teeth and nails. Thus, the availability of YORVIPATH offers new hope for individuals living with chronic hypoparathyroidism.
YORVIPATH was developed using Ascendis Pharma’s innovative TransCon technology platform. This platform seeks to optimize the therapeutic potential of existing drugs by creating prodrugs, which are modified versions of the original drugs. Prodrugs like YORVIPATH are designed to improve drug delivery, enhance therapeutic efficacy, and reduce the frequency and burden of administration for patients. With this technology, Ascendis Pharma aims to transform the treatment landscape for a variety of rare endocrine disorders.
The approval and availability of YORVIPATH in Germany and Austria mark a significant milestone for Ascendis Pharma and the chronic hypoparathyroidism community. Patients in these countries now have access to a novel therapy that addresses the underlying cause of their condition, offering them a chance for improved quality of life and symptom management.
Dr. Jan Mikkelsen, MD, Ascendis Pharma’s President and Chief Executive Officer, expressed his excitement about the launch of YORVIPATH, stating, We are thrilled to provide another treatment option for adults with chronic hypoparathyroidism in Germany and Austria. Dr. Mikkelsen further emphasized the company’s commitment to developing innovative therapies for this underserved patient population.
The launch of YORVIPATH in Germany and Austria is expected to have a positive impact on the lives of many patients, enabling them to regain control over their condition and experience relief from debilitating symptoms. The availability of this therapy reinforces Ascendis Pharma’s dedication to advancing the field of endocrinology, bringing much-needed solutions to patients suffering from rare hormonal disorders.
In summary, Ascendis Pharma’s commercial launch of YORVIPATH in Germany and Austria marks a significant milestone for both the company and the chronic hypoparathyroidism community. This innovative therapy, developed using the TransCon technology platform, offers hope to patients by addressing the underlying cause of their condition and providing effective symptom management. With the launch of YORVIPATH, Ascendis Pharma continues to demonstrate its commitment to improving the lives of individuals living with rare endocrine disorders.
Comments